MK-677 (Ibutamoren) Research Guide: GHS-R1a Mechanism, Preclinical GH-Axis Literature, and Verification

Most of the compounds in a growth-hormone-axis research library are peptides — short chains of amino acids that engage the ghrelin receptor and then are rapidly cleared. MK-677 is the exception that proves the rule. It is not a peptide at all. It is a small, orally stable molecule that Merck chemists designed in the early 1990s to do everything the peptide secretagogues do — bind the same receptor, trigger the same second-messenger cascade, release the same hormone — while surviving the gut and the first pass through the liver. That design goal, a non-peptide that mimics a peptide’s pharmacology, is exactly what makes MK-677 (ibutamoren) a distinctive reference compound. For a laboratory comparing peptidyl secretagogues such as GHRP-6, hexarelin, or ipamorelin against a stable non-peptide benchmark, MK-677 is the standard. This guide surveys it at the molecular and preclinical level: what it is, how it engages its receptor, what the primary literature actually reports, and how a research group should evaluate the material it sources.

The information below is provided for in-vitro and preclinical laboratory research context only. Nothing here describes human use, dosing, or therapeutic outcomes.

Section 1 — Molecular Profile

MK-677 is a synthetic, non-peptidic growth hormone secretagogue built on a spiroindoline-piperidine scaffold. It was developed at Merck under the designation L-163,191 (later MK-0677) and is the culmination of a medicinal-chemistry program aimed at replacing the peptide backbone of earlier secretagogues with a metabolically stable small-molecule frame.

MK-677 (ibutamoren)

• CAS number: 159634-47-6 (free base); 159752-10-0 (mesylate salt)
• Molecular formula: C27H36N4O5S (free base)
• Molecular weight: approximately 528.67 g/mol (528.7 Da) for the free base
• Class: non-peptidic spiropiperidine growth hormone secretagogue; orally active ghrelin-receptor (GHS-R1a) agonist
• Also known as: MK-0677, L-163,191, ibutamoren, ibutamoren mesylate
• Chemical name: (R)-2-amino-N-[2-(benzyloxy)-1-[1-(methylsulfonyl)spiro[indoline-3,4′-piperidine]-1′-yl]-1-oxopropan-2-yl]-2-methylpropanamide

Two features of the molecule define its research behavior. First, there is no amino-acid sequence to report, because MK-677 is a peptidomimetic rather than a peptide — its activity comes from a rigid spiro scaffold that presents the right pharmacophore to the ghrelin receptor without any peptide bonds for peptidases to cleave. This is the whole point of the molecule: where a hexapeptide such as GHRP-6 is degraded quickly by native proteases, MK-677 is reported to have greater than 60% oral bioavailability and a plasma half-life on the order of 4.7 hours, giving it a fundamentally different pharmacokinetic profile from its peptide counterparts. Second, the compound is typically supplied as the mesylate salt, which is why the salt carries its own distinct CAS number (159752-10-0) and why quantitative work should reference the salt form actually present in the vial rather than assuming free-base mass. These distinctions — small molecule versus peptide, free base versus mesylate — are precisely the details a lot-specific analytical file exists to confirm.

Section 2 — Mechanism

MK-677’s mechanism is best described at the level of a single receptor, because unlike the dual-receptor peptide GHRP-6, MK-677 is characterized primarily as a selective agonist of one target.

That target is the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same G-protein-coupled receptor that is the endogenous target of the hormone ghrelin. MK-677 binds GHS-R1a with high affinity (reported in the sub-nanomolar range, on the order of 0.4 nM) and is described in the literature as an orally active ghrelin mimetic: a molecule that reproduces ghrelin’s receptor pharmacology through an entirely synthetic structure. On binding, GHS-R1a couples preferentially to the Gq/11 class of G-proteins. This activates phospholipase C-beta, which hydrolyzes membrane phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from intracellular stores while DAG activates protein kinase C, and the resulting rise in intracellular calcium in anterior-pituitary somatotrophs is the proximate trigger for growth hormone release. Critically for in-vitro work, GHS-R1a is expressed on somatotrophs independently of hypothalamic input, so this Gq/IP3/calcium cascade can be studied in isolated primary pituitary-cell preparations where hypothalamic connections have been removed.

The original characterization by Patchett and colleagues established that MK-677’s precursor, L-163,191, releases growth hormone from rat pituitary cells in culture with an EC50 near 1.3 nM and is mechanistically indistinguishable from the growth hormone-releasing peptide GHRP-6 and the earlier nonpeptide secretagogue L-692,429. In whole-animal work the same study reported growth hormone release without significant effect on plasma aldosterone, luteinizing hormone, thyroxine, or prolactin — the receptor selectivity that made the molecule a landmark tool compound. At the level of the intact axis, ghrelin-receptor agonists are understood to amplify growth hormone secretion through more than one node: a direct action on pituitary somatotrophs, an indirect action involving hypothalamic growth hormone-releasing hormone (GHRH), and a functional opposition to the inhibitory tone of somatostatin. This multi-node engagement distinguishes the Gq/calcium GHS-R1a route that MK-677 activates from the Gαs/cAMP GHRH-receptor route engaged by GHRH analogs such as sermorelin or tesamorelin.

For research design, the practical takeaway is that MK-677 is the prototypical non-peptide GHS-R1a agonist — a stable reference ligand for the Gq/calcium arm of ghrelin-receptor pharmacology that, unlike the peptide secretagogues, does not depend on a labile peptide backbone. Everything in this article stays at exactly that level: receptor binding, second-messenger generation, and cell- and tissue-model responses.

Section 3 — Preclinical Research Data

The dataset around MK-677 opens with the receptor pharmacology that defined the molecule. The foundational medicinal-chemistry work characterized L-163,191/MK-0677 as an orally active secretagogue that releases growth hormone from cultured pituitary cells in the low-nanomolar range and remains active after oral dosing in dogs at doses as low as 0.125 mg/kg — a combination of potency and oral stability that no earlier peptide secretagogue had matched. Radioligand and reporter-assay work situated the molecule firmly at GHS-R1a, and its mechanistic equivalence to GHRP-6 in vitro made it the definitive proof that a non-peptide could reproduce peptide-secretagogue pharmacology.

Beyond the pituitary, the published literature examines MK-677’s action on the broader growth hormone/insulin-like growth factor-I (GH/IGF-I) axis. Endocrine studies reported that daily oral administration of MK-677 raised circulating growth hormone and IGF-I into a defined range while preserving the natural pulsatile rhythm of secretion rather than flattening it — a pharmacodynamic signature repeatedly described across the endocrine literature. Additional published work evaluated markers of bone turnover, sleep-architecture endpoints, and the responsiveness of the axis in growth-hormone-deficient states. A later long-duration study by Nass and colleagues evaluated body-composition and clinical endpoints in older adults over twelve months, reporting sustained enhancement of pulsatile growth hormone secretion. These are described here strictly as the endpoints those published studies measured — endocrine-axis and body-composition parameters recorded in clinical and preclinical research — not as outcomes attributed to any PYXAX product.

Across these datasets the recurring research themes are receptor selectivity, oral stability, and axis-level pharmacodynamics: MK-677’s clean GHS-R1a agonism is what made it a benchmark tool compound, and its non-peptide stability is what allowed investigators to study sustained axis engagement in a way the rapidly cleared peptides do not permit. All of the findings above are cited as published research context only.

Section 4 — Published Literature

The following are real, published, peer-reviewed references useful for an MK-677 research library:

• Patchett AA, Nargund RP, Tata JR, et al. “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.” Proceedings of the National Academy of Sciences USA, 1995; 92(15):7001–7005 (PMID 7624358).
• Chapman IM, Bach MA, Van Cauter E, et al. “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects.” Journal of Clinical Endocrinology & Metabolism, 1996; 81(12):4249–4257 (PMID 8954023).
• Chapman IM, Pescovitz OH, Murphy G, et al. “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.” Journal of Clinical Endocrinology & Metabolism, 1997; 82(10):3455–3463 (PMID 9329386).
• Murphy MG, Bach MA, Plotkin D, et al. “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults.” Journal of Bone and Mineral Research, 1999; 14(7):1182–1188.
• Nass R, Pezzoli SS, Oliveri MC, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.” Annals of Internal Medicine, 2008; 149(9):601–611 (PMID 18981485).
• Sevigny JJ, Ryan JM, van Dyck CH, et al. “Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.” Neurology, 2008; 71(21):1702–1708.

These references trace MK-677 from its original design and receptor characterization, through the endocrine studies mapping its action on the GH/IGF-I axis, to the long-duration and disease-model trials that define the boundaries of what the molecule does and does not do — the primary literature a research group needs to design and interpret in-vitro work.

Section 5 — Research Applications (In-Vitro)

Within a laboratory research context, MK-677 is studied for a set of overlapping, model-system purposes:

• Non-peptide GHS-R1a agonist reference ligand: calcium-flux, inositol-phosphate, and reporter assays in ghrelin-receptor-expressing cell lines, using MK-677 as the stable small-molecule comparator against ghrelin and against peptidyl secretagogues such as GHRP-6, hexarelin, and ipamorelin.
• Pathway-selectivity work: contrasting the Gq/phospholipase-C/calcium GHS-R1a route that MK-677 engages with the Gαs/cAMP GHRH-receptor route engaged by GHRH analogs, making MK-677 a foundational counterpart ligand for mapping GH-axis pharmacology.
• Peptide-versus-nonpeptide benchmarking: using MK-677 as the stable reference against which the potency and metabolic lability of engineered peptide secretagogues are measured in parallel assays.
• Somatotroph signaling models: isolated primary pituitary-cell and somatotroph-line preparations used to study direct, hypothalamus-independent activation of the Gq/IP3/calcium cascade.
• Analytical method development: as a non-peptide of defined mass, MK-677 is a useful orthogonal test article for validating LC-MS identity workflows and HPLC methods alongside the peptide secretagogues, since it separates and ionizes differently from the peptidyl compounds in the same library.

Every one of these applications is an in-vitro or model-system use. None involves administration to humans or animals for outcome measurement.

Section 6 — How to Evaluate a Source

Because research-grade MK-677 is supplied as a research chemical rather than a finished pharmaceutical preparation, documentation is the only meaningful quality signal. When comparing suppliers, researchers should look for:

• A lot-specific Certificate of Analysis (COA) that names the exact batch it describes, not a generic marketing spec sheet.
• HPLC purity data with a visible chromatogram rather than a bare percentage figure — important for a small molecule where synthetic byproducts and residual solvents can arise from the multi-step spiro-scaffold synthesis.
• LC-MS or MS identity confirmation of the target mass (~528.7 Da for the free base), essential to distinguish genuine MK-677 from mislabeled or substituted material, and to confirm whether the vial contains free base or mesylate salt.
• Endotoxin and heavy-metal testing for material intended for cell-based work.
• An independent, accredited testing laboratory named on the COA and verifiable at that lab’s own domain, rather than a screenshot hosted by the vendor.

As a market-context note, MK-677 is one of the most widely sold research compounds in the growth-hormone-secretagogue category, which means the range of quality on offer is unusually wide — from genuinely well-characterized, fully documented material to under-characterized product sold on price alone. Because it is a small molecule rather than a peptide, some buyers wrongly assume identity is trivial to confirm; in practice, structurally related impurities and outright substitutions are common, and only orthogonal analytical data settles the question. Cost signals nothing about identity or purity; a low price attached to no verifiable COA is a red flag, not a bargain.

Section 7 — The PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

For a non-peptide secretagogue like MK-677, orthogonal identity testing is not optional. It is the only way to confirm that a vial labeled as MK-677 contains the correct spiroindoline-piperidine structure at the expected ~528.7 Da mass — rather than a structurally related impurity, a mislabeled substitute, or the wrong salt form — and that a lyophilized or crystalline lot is clean enough for cell-based work. PYXAX publishes available lot-specific analytical files in the COA Library rather than substituting a generic spec sheet. Explore the current verification documents in the COA library at /coa-library/, review the PYXAX analytical standard at /standard/, and see available research compounds at /shop/. Product-specific data is linked from each listing at /product/mk-677-ibutamoren/.

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.